Choice of high-dose intravenous iron preparation determines hypophosphatemia risk

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Schaefer, Benedikt ^a   Würtinger, Philipp ^b   Finkenstedt, Armin ^a   Braithwaite, Vickie ^c   Viveiros, André ^a   Effenberger, Maria ^a   Sulzbacher, Irene ^d   Moschen, Alexander ^a   Griesmacher, Andrea ^b   Tilg, Herbert ^a   Vogel, Wolfgang ^a   Zoller, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FERRIC CARBOXYMALTOSE; IRON ISOMALTOSE; PHOSPHATE; BIOLOGICAL MARKER; DISACCHARIDE; FERRIC ION; IRON ISOMALTOSIDE 1000; MALTOSE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; HIGH RISK PATIENT; HUMAN; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; RISK ASSESSMENT; UNIVERSITY HOSPITAL; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; RISK;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; DISACCHARIDES; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; MALE; MALTOSE; MIDDLE AGED; PHOSPHATES; PREVALENCE; RETROSPECTIVE STUDIES; RISK;

EID: 84999666516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167146     Document Type: Article

References (25)

1. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. The American journal of gastroenterology. 2008; 103(5):1182-92. doi: 10.1111/j.1572-0241.2007.01744.x PMID: 18371137
2. Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015; 50(10):1226-33. PubMed Central PMCID: PMCPMC4673551. doi: 10.3109/00365521.2015.1031168 PMID: 25900645
3. Dignass AU, Gasche C, Bettenworth D, Birgegard G, Danese S, Gisbert JP, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015; 9(3):211-22. Epub 2014/12/18. doi: 10.1093/ecco-jcc/jju009 PMID: 25518052
4. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C, et al. UK guidelines on the management of iron deficiency in pregnancy. British journal of haematology. 2012; 156(5):588-600. PMID: 22512001
5. Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs. 2015; 75(1):101-27. Epub 2014/11/28. doi: 10.1007/s40265-014-0332-3 PMID: 25428711
6. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141(3):846-53 e1-2. doi: 10.1053/j.gastro.2011.06.005 PMID: 21699794
7. New Drug Application (NDA) 22-054 for Injectafer (Ferric Carboxymaltose) for the treatment of iron deficiency anemia in patients with heavy uterine bleeding or postpartum patients FDA Advisory Committee Briefing Document. 2008.
8. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49(12):2719-28. Epub 2009/08/18. doi: 10.1111/j.1537-2995.2009. 02327.x PMID: 19682342
9. Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014; 54(2):306-15. doi: 10.1111/trf.12289 PMID: 23772856
10. Soeren AS, Claes CS, Lars LT. Phosphate levels after iron isomaltoside administration. Poster European Iron Club Meeting 2016, Innsbruck. 2016.
11. Barea Mendoza JA, Gredilla Zubiria I, Gonzalez Olmedo J, Mateo Alvarez S. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron]. Medicina clinica. 2014; 143(6):284-5. doi: 10.1016/j.medcli.2013.11.030 PMID: 24461741
12. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. The Netherlands journal of medicine. 2014; 72(1):49-53. Epub 2014/01/25. PMID: 24457442
13. Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti Bertrand P. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. European journal of clinical nutrition. 2014; 68(4):531-3. doi: 10.1038/ejcn.2014.20 PMID: 24569537
14. Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010; 90(7):804-5. Epub 2010/10/01. doi: 10.1097/TP.0b013e3181f00a18 PMID: 20881582
15. Moore KL, Kildahl-Andersen O, Kildahl-Andersen R, Tjonnfjord GE. Uncommon adverse effect of a common medication. Tidsskr Nor Laegeforen. 2013; 133(2):165. doi: 10.4045/tidsskr.12.0494 PMID: 23344600
16. Poursac N. Hypophosphatémie et FGF23 élevé. Rhumatos. 2015; 12(105):61-4.
17. Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature. Case Rep Endocrinol. 2014; 2014:843689. PubMed Central PMCID: PMCPMC4247964. doi: 10.1155/2014/843689 PMID: 25478250
18. Sangros Sahun MJ, Goni Girones E, Camarero Salazar A, Estebanez Estebanez C, Lozano Martinez ME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016.
19. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2013; 28(8):1793-803.
20. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014; 23(4):411-9. Epub 2014/05/29. PubMed Central PMCID: PMCPMC4322859. doi: 10.1097/01.mnh.0000447020.74593.6f PMID: 24867675
21. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. NIH publication. 2009; # 09-7473.
22. Finch PJ, Ang L, Eastwood JB, Maxwell JD. Clinical and histological spectrum of osteomalacia among Asians in south London. Q J Med. 1992; 83(302):439-48. PMID: 1448545
23. Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. The American journal of medicine. 2000; 108(4):296-300. Epub 2000/10/03. PMID: 11014722
24. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (46):E1146-55. PubMed Central PMCID: PMC3219119. doi: 10.1073/pnas.1110905108 PMID: 22006328
25. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney international. 2015.